Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Cross-Sectional Study

An Exploration of Some Predictors of Quality of Life-Related to the Innate Immune System, Inflammation, and Disease Activity in Patients with Behcet's Syndrome: An Analytical Cross-sectional Study

Author(s): Amir Hossein Faghfouri*, Seyyed Morteza Seyyed Shoura, Shahab Papi, Alireza Khabbazi, Behzad Baradaran, Mohaddeseh Badpeyma and Elnaz Faghfuri*

Volume 20, Issue 2, 2024

Published on: 16 October, 2023

Page: [200 - 207] Pages: 8

DOI: 10.2174/1573397119666230907101558

Price: $65

Abstract

Background: Behçet's disease (BD) has a growing prevalence in Silk Road countries. The aim of our cross-sectional study was to explore the clinical and molecular predictors of quality of life in BD patients.

Materials and Methods: One hundred and fifty consecutive Iranian BD patients with an age range between 20-50 years were included. The Leeds Behçet's disease quality of life (BDQoL) in Persian form was fulfilled to evaluate the quality of life. Anthropometric measurements were carried out using the calibrated scales. Iranian Behcet's Disease Dynamic Activity Measure (IBDDAM), Behcet's disease current activity form (BDCAF), and Total Inflammatory Activity Index (TIAI) were used to assess BD activity. mRNA expression of toll-like receptors 2 and 4 (TLR2 and TLR4) and tumor-necrosis-factor-alpha (TNF-α) levels in serum were measured by real-time polymerase chain reaction (PCR) and ELISA, respectively. Multiple linear backward regression at P = 0.1 was used to study the potential predictors of quality of life.

Results: TLR2 and BDCAF were shown to be the most important predictors of quality of life in BD patients by 22%. There were positive associations between them (β = 0.326, p = 0.013 for BDCAF; β = 0.366, p = 0.006 for TLR2) and BDQoL value.

Conclusion: Higher TLR2 expression as a key protein in recognizing pathogens by innate immunity and BDCAF value as a comprehensive BD assessing scale contribute to poor quality of life among BD patients. Emphasizing therapeutically, approaches associated with lower TLR2 expression and BDCAF value can be considered in future studies.

« Previous Next »
[1]
Nair JR, Moots RJ. Behcet’s disease. Clin Med 2017; 17(1): 71-7.
[http://dx.doi.org/10.7861/clinmedicine.17-1-71] [PMID: 28148585]
[2]
Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999; 54(3): 213-20.
[http://dx.doi.org/10.1034/j.1399-0039.1999.540301.x] [PMID: 10519357]
[3]
Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45(2): 202-7.
[http://dx.doi.org/10.1038/ng.2520] [PMID: 23291587]
[4]
Mumcu G, Direskeneli H. Triggering agents and microbiome as environmental factors on Behçet’s syndrome. Intern Emerg Med 2019; 14(5): 653-60.
[http://dx.doi.org/10.1007/s11739-018-2000-1] [PMID: 30523495]
[5]
Wu YH, Yu-Fong Chang J, Wang YP, Wu YC, Chen HM, Sun A. Hemoglobin, iron, vitamin B12, and folic acid deficiencies and hyperhomocysteinemia in Behcet’s disease patients with atrophic glossitis. J Formos Med Assoc 2018; 117(7): 559-65.
[http://dx.doi.org/10.1016/j.jfma.2018.03.005] [PMID: 29572125]
[6]
Faezi ST, Ansari N, Paragomi P, Akhlaghi M, Ghanavat M, Davatchi F. Vitamin D deficiency in patients with Behcet’s disease. J Diabetes Metab Disord 2014; 13(1): 18.
[http://dx.doi.org/10.1186/2251-6581-13-18] [PMID: 24451043]
[7]
Mendes D, Correia M, Barbedo M, et al. Behçet’s disease - a contemporary review. J Autoimmun 2009; 32(3-4): 178-88.
[http://dx.doi.org/10.1016/j.jaut.2009.02.011] [PMID: 19324519]
[8]
Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: Epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 2017; 13(1): 57-65.
[http://dx.doi.org/10.1080/1744666X.2016.1205486] [PMID: 27351485]
[9]
Group W. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993; 2(2): 153-9.
[http://dx.doi.org/10.1007/BF00435734] [PMID: 8518769]
[10]
Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: A quality of life measure specific to Behçet’s disease. J Rheumatol 2004; 31(5): 931-7.
[PMID: 15124253]
[11]
Vojdanian M, Faezi ST, Tennant A, et al. Validity and reliability of the Persian version of Behçet’s disease quality-of-life (BD-QoL) questionnaire: A cross-cultural adaptation. Rheumatol Int 2015; 35(4): 677-84.
[http://dx.doi.org/10.1007/s00296-014-3128-6] [PMID: 25216713]
[12]
Touma Z, Ghandour L, Sibai A, et al. Cross-cultural adaptation and validation of Behçet’s disease quality of life questionnaire. BMC Med Res Methodol 2011; 11(1): 52.
[http://dx.doi.org/10.1186/1471-2288-11-52] [PMID: 21507231]
[13]
Yi SW, Kim JH, Lim KY, Bang D, Lee S, Lee ES. The Behcet’s Disease Quality of Life: Reliability and validity of the Korean version. Yonsei Med J 2008; 49(5): 698-704.
[http://dx.doi.org/10.3349/ymj.2008.49.5.698] [PMID: 18972588]
[14]
Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: Evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38(8): 728-33.
[http://dx.doi.org/10.1093/rheumatology/38.8.728] [PMID: 10501420]
[15]
Davatchi F, Akbarian M, Shahram F, Tebbi M, Chams C, Chams H. Iran Behcet’s disease dynamic activity measure. Iran Behcet’s disease dynamic activity measure Abstracts of the XIIth European congress of rheumatology: Hung Rheumatol. 32: 134.
[16]
Davatchi F, Shams H, Shahram F, Nadji A, Jamshidi AR, Shams Davachi SH. How much improvement is expected in ocular lesions of behçet’s disease treated with pulse cyclophosphamide? Iran J Med Sci 2005; 30(3): 101-4.
[17]
Gorial FI, Jabbar MA. Impact of disease activity on health related quality of life in patients with Behçet’s disease: A cross-sectional study. Ann Med Surg 2020; 54: 43-6.
[http://dx.doi.org/10.1016/j.amsu.2020.03.010] [PMID: 32368339]
[18]
Fabiani C, Vitale A, Orlando I, et al. Quality of life impairment in Behçet’s disease and relationship with disease activity: A prospective study. Intern Emerg Med 2017; 12(7): 947-55.
[http://dx.doi.org/10.1007/s11739-017-1691-z] [PMID: 28620840]
[19]
Melikoğlu M, Melikoglu MA. What affects the quality of life in patients with Behcet’s disease? Acta Reumatol Port 2014; 39(1): 46-53.
[PMID: 24811461]
[20]
Khabbazi A, Attari EV, Jafarabadi AM, Mahdavi MA. Quality of life in patients with behçet disease and its relation with clinical symptoms and disease Activity. Clin Rheumatol 2021; 17(1): 1-6.
[http://dx.doi.org/10.1016/j.reumae.2019.03.009] [PMID: 31078452]
[21]
van der Houwen TB, Dik WA, Goeijenbier M, et al. Leukocyte toll-like receptor expression in pathergy positive and negative Behçet’s disease patients. Rheumatology 2020; 59(12): 3971-9.
[http://dx.doi.org/10.1093/rheumatology/keaa251] [PMID: 32756992]
[22]
Diez-Pina JM, Fernandez J. Llorente, Diaz-Lobato S, Mayoralas S, Florez A. Tumor necrosis factor alpha as a marker of systemic and local inflammation in “healthy” smokers. Int J Gen Med 2009; 2: 9-14.
[http://dx.doi.org/10.2147/IJGM.S4723] [PMID: 20360881]
[23]
Grassin-Delyle S, Abrial C, Salvator H, Brollo M, Naline E, Devillier P. The role of toll-like receptors in the production of cytokines by human lung macrophages. J Innate Immun 2020; 12(1): 63-73.
[http://dx.doi.org/10.1159/000494463] [PMID: 30557876]
[24]
S Lashkari B. Anumba DO. Estradiol alters the immune-responsiveness of cervical epithelial cells stimulated with ligands of Toll-like receptors 2 and 4. PLoS One 2017; 12(3): e0173646.
[http://dx.doi.org/10.1371/journal.pone.0173646] [PMID: 28296959]
[25]
Davatchi F. Diagnosis/classification criteria for behcet’s disease. Pathol Res Int 2012; 2012: 1-5.
[http://dx.doi.org/10.1155/2012/607921] [PMID: 21961081]
[26]
Faghfouri AH, Khabbazi A, Baradaran B, et al. Immunomodulatory and clinical responses to zinc gluconate supplementation in patients with Behçet’s disease: A double-blind, randomized placebo-controlled clinical trial. Clin Nutr 2022; 41(5): 1083-92.
[http://dx.doi.org/10.1016/j.clnu.2022.03.019] [PMID: 35413570]
[27]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔ. CT Method Methods 2001; 25(4): 402-8.
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[28]
Gupta A, Mishra P, Pandey CM, Singh U, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth 2019; 22(1): 67-72.
[http://dx.doi.org/10.4103/aca.ACA_157_18] [PMID: 30648682]
[29]
Wyse C, O’Malley G, Coogan AN, McConkey S, Smith DJ. Seasonal and daytime variation in multiple immune parameters in humans: Evidence from 329,261 participants of the UK Biobank cohort. iScience 2021; 24(4): 102255.
[http://dx.doi.org/10.1016/j.isci.2021.102255] [PMID: 33817568]
[30]
Faghfouri AH, Zarrin R, Maleki V, Payahoo L, Khajebishak Y. A comprehensive mechanistic review insight into the effects of micronutrients on toll-like receptors functions. Pharmacol Res 2020; 152: 104619.
[http://dx.doi.org/10.1016/j.phrs.2019.104619] [PMID: 31887355]
[31]
Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of TLR2 and 4 in Behçet’s disease pathogenesis. Innate Immun 2014; 20(4): 412-22.
[http://dx.doi.org/10.1177/1753425913498042] [PMID: 23940075]
[32]
Liu X, Wang C, Ye Z, Kijlstra A, Yang P. Higher expression of Toll-like receptors 2, 3, 4, and 8 in ocular Behcet’s disease. Invest Ophthalmol Vis Sci 2013; 54(9): 6012-7.
[http://dx.doi.org/10.1167/iovs.13-12159] [PMID: 23908180]
[33]
van der Houwen T, van Laar J. Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers. Int J Mol Sci 2020; 21(9): 3072.
[http://dx.doi.org/10.3390/ijms21093072] [PMID: 32349254]
[34]
Walker SL, Roberts CH, Atkinson SE, et al. The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions. Br J Dermatol 2012; 167(1): 29-35.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10891.x] [PMID: 22348338]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy